Emergent BioSolutions Receives Paul-Ehrlich-Institut Approval to Market BioThrax in Germany

Published: Jul 01, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI) has approved Emergent’s marketing authorization application for BioThrax® (Anthrax Vaccine Adsorbed) in Germany. BioThrax is the only vaccine licensed by the U.S. Food and Drug Administration (FDA) for the prevention of anthrax disease.

Help employers find you! Check out all the jobs and post your resume.

Back to news